Stocks Merck & Co Inc

  • Gardasil.jpg

    Two prominent articles in a major medical journal are examining the cost benefits and safety of an expensive, controversial vaccine for a sexually-transmitted disease and cancer.

  • To give investors an edge, CNBC asked the experts for their best trades now.

  • The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.

  • Stocks closed lower, hurt by rising oil prices and fresh worries about the financial sector, though the market ended off its lows for the day.

  • Stocks opened lower amid signs that the consumer was buying fewer goods that will cost more in the future.

  • Elan

    The Elanians have been pretty quiet in the wake of last week's bad news. and the stock getting about a two-thirds haircut. And I don't mean to rub salt in the wound.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • Stocks pulled off modest gains Friday as enthusiasm for some better-than-expected economic reports outshined a warning from S&P of a possible downgrade on Fannie Mae and Freddie Mac.

  • On a heavy earnings week with over 30% of the S&P 500 reporting, the markets end the week mixed on positive economic data and a decline in oil prices to an almost two-month low.  The Dow and S&P are both down for the week while the NASDAQ ends the week up about 1.2%. 

  • Heart Stent

    Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.

  • pfizer_hq.jpg

    Pfizer Wednesday said quarterly earnings more than doubled on higher sales of its prescription drugs and lower expenses, but its Chantix quit-smoking drug lost more than a third of its U.S. sales amid safety concerns.

  • If only Merck could develop a treatment for this malady...

  • Stocks surged in the final hour of trading as a sharp drop in oil prices and an analyst note prompted a late rally in financials. The Nasdaq eked out a gain but investors still punished select techs, including Apple and Texas instruments after the firms dispatched disappointing results.

  • Stocks advanced, buoyed by a sharp drop in oil prices, but technology stocks dragged on the market after disappointing earnings from Apple and Texas Instruments.

  • Sex and The the City

    Recently I blogged about Merck advertising its cervical cancer vaccine Gardasil to a captive audience during trailers for the "Sex and the City" movie.

  • Stocks advanced, buoyed by a sharp drop in oil prices, but technology stocks dragged on the market after disappointing earnings from Apple and Texas Instruments.

  • Vince Farrell

    The average bear market shows a decline of 30%, but then has an average 30% plus bounce when the bottom is reached. We are off more than 20% so it's possible the end is in sight.

  • vytorin_logo.jpg

    Yesterday while covering the press conference about the new study on Merck and Schering-Plough's Vytorin I quoted the lead researcher, Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway, who said--and this is a direct quote: "However, we had a disturbing finding when we looked at safety."

  • graphic_word_ofthe_street.jpg

    Based on the action after hours it looks like a rough open on Tuesday. What's the "Word on the Street?"

  • Stocks slipped as the bank rally that has stretched four sessions appeared to run out of steam ahead of Wachovia's report. Merck fell following disappointing results from a cholesterol-drug study.